Literature DB >> 35543484

The potential confounders hiding in a US cohort about SARS-CoV-2 infection during pregnancy.

Shih Pei-Yun1, Ying-Hsiang Chou2,3, James Cheng-Chung Wei4,5,6.   

Abstract

Entities:  

Year:  2022        PMID: 35543484      PMCID: PMC9384014          DOI: 10.1093/infdis/jiac193

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


× No keyword cloud information.
to the editor—With great interest, we read the article by Regan et al [1]. In their cohort study, the authors investigated the association between prenatal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and increased risk of adverse pregnancy outcomes. These findings support previous studies that suggest maternal SARS-CoV-2 infection harms fetal health. However, there are some issues that should be discussed. First, SARS-CoV-2 infection may not be the only risk factor of adverse pregnancy outcomes after adjustment in this cohort. This study was based on de-identified administrative claims and electronic health records data from OptumLabs Data Warehouse [2]. However, some confounders recorded in electronic health records data were not considered in this study, such as parity. A comparative study showed that primary cesarean delivery contributes to the increasing rate of patients’ refusal to undergo vaginal delivery, thus inducing the secondary or repeat cesarean delivery [3]. Moreover, SARS-CoV-2–infected pregnancy complicated with high-risk gestational factors should be considered when evaluating the risk of adverse pregnancy outcomes. For example, previous studies indicated that maternal obesity is linked to a greater risk of preterm birth [4]. As a result, we suggest that importing the known residual confounders into the adjusted model would improve the precision of this study. Second, personal factors were effect modifiers for the association between coronavirus disease 2019 (COVID-19) and clinician-initiated events, including induced abortion, cesarean delivery, and clinician-initiated preterm birth. The administrative codes cannot reflect the exact condition. The preference of patients may influence the decisions of the doctors [3]. On the other hand, doctors may execute clinician-initiated events for COVID-19 patients for other reasons than SARS-CoV-2 infection. The personal factors were residual confounders to the outcomes. Owing to the large infected-to-uninfected ratio in this study, we propose that matching the infected and uninfected cases by time-dependent propensity score matching can minimize the impact of the residual confounders [5]. After sequential matching with time-dependent propensity score, the effect of exposure can be identified by the Cox regression model used in this cohort.
  4 in total

1.  The Relevance of the Second Cesarean Delivery in the Reduction of Institutional Cesarean Delivery Rates.

Authors:  Michael F E Diejomaoh; Waleed Al-Jassar; Zainab Bello; Kavitha Karunakaran; Asiya Mohammed
Journal:  Med Princ Pract       Date:  2018-08-30       Impact factor: 1.927

Review 2.  Risks associated with obesity in pregnancy, for the mother and baby: a systematic review of reviews.

Authors:  J Marchi; M Berg; A Dencker; E K Olander; C Begley
Journal:  Obes Rev       Date:  2015-05-28       Impact factor: 9.213

Review 3.  Propensity score analysis for time-dependent exposure.

Authors:  Zhongheng Zhang; Xiuyang Li; Xiao Wu; Huixian Qiu; Hongying Shi
Journal:  Ann Transl Med       Date:  2020-03

4.  SARS-CoV-2 Infection During Pregnancy and Associated Perinatal Health Outcomes: A National US Cohort Study.

Authors:  Annette K Regan; Onyebuchi A Arah; Deshayne B Fell; Sheena G Sullivan
Journal:  J Infect Dis       Date:  2022-03-02       Impact factor: 5.226

  4 in total
  1 in total

1.  Analyzing uncontrolled confounding of the perinatal health effects of SARS-CoV-2 infection during pregnancy.

Authors:  Onyebuchi A Arah; Sheena G Sullivan; Deshayne B Fell; Annette K Regan
Journal:  J Infect Dis       Date:  2022-05-11       Impact factor: 7.759

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.